A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

التفاصيل البيبلوغرافية
العنوان:	A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
المؤلفون:	Chelariu-Raicu, Anca, Nick, Alpa, Urban, Renata, Gordinier, Mary, Leuschner, Carola, Bavisotto, Linda, Molin, Graziela Zibetti Dal, Whisnant, John K., Coleman, Robert L.
المصدر:	In Gynecologic Oncology February 2021 160(2):418-426
قاعدة البيانات:	ScienceDirect

كن أول من يترك تعليقا!